If you’ve worked in UK healthcare for any length of time, you’ve probably experienced a sense of déjà vu.
Another NHS reform. Another operating model. Another ambition to move care closer to home, focus on prevention and reduce pressure on hospitals.
Recently, the Chair of NHS England called for an urgent redesign of urgent and emergency care, warning that the current model is not delivering what patients need. The argument itself is familiar. What is more interesting is what sits behind it: an acknowledgement that knowing what needs to change and making change happen are two very different things.
That lesson extends far beyond urgent and emergency care.
The gap between ambition and implementation
A year on from the NHS 10-Year Health Plan, the direction of travel is becoming clear. Prevention, neighbourhood health, integrated care, workforce transformation and digital enablement remain central priorities. Yet implementation remains uneven, with local systems progressing at very different speeds. National frameworks exist, but local readiness varies considerably.
For healthcare companies, this creates a challenge.
Many organisations continue to think about market access as a national exercise. Secure NICE approval, achieve a positive reimbursement outcome and uptake should follow.
The reality is more complex.
Even where national support exists, local funding arrangements, workforce capacity, service design and pathway requirements often determine whether innovation is adopted in practice. National approval may open the door, but local implementation determines whether anyone walks through it.
Why good ideas struggle to become routine care
The challenge facing the NHS is rarely a lack of good ideas.
Most healthcare leaders would agree on the importance of prevention. Few would argue against integrated care, earlier intervention or better management of long-term conditions.
The difficult part is translating these ambitions into everyday clinical practice.
Recent comments from NHS leadership on obesity illustrate this perfectly. The Chair of NHS England highlighted concerns about declining breastfeeding support, arguing that the health service is failing to promote an intervention that could significantly reduce obesity risk. The issue is not that the evidence is unavailable. The issue is turning evidence into consistent implementation across the system.
This pattern repeats itself throughout healthcare, the challenge applies to medicines, diagnostics, digital technologies and healthcare services.
Evidence exists. Guidance exists. Policy exists. Adoption varies.
The local NHS matters more than ever
One of the strongest signals emerging from the NHS 10-Year Health Plan is the increasing importance of neighbourhood and place-based healthcare. Care is gradually shifting away from traditional acute settings towards community-based models, multidisciplinary teams and local partnerships.
For life sciences companies, this changes the commercialisation challenge.
Understanding NICE remains important.
Understanding local systems is becoming essential.
Integrated Care Systems, Primary Care Networks, community providers, finance leads, pathway owners and voluntary sector organisations are playing an increasingly influential role in determining how innovation is adopted. A single national strategy is unlikely to be sufficient in a system where priorities, capabilities and readiness differ significantly between geographies.
The organisations seeing the greatest success are not necessarily those with the strongest national proposition. They are often the ones that understand local barriers, engage the right stakeholders and support implementation after launch.
Commercialisation is no longer just market access
Historically, many organisations viewed market access and commercialisation as separate activities.
Market access focused on reimbursement and approval.
Commercial teams focused on launch and uptake.
Those boundaries are becoming increasingly blurred.
Today’s NHS is looking for solutions that demonstrate clinical value, workforce impact, operational feasibility and financial sustainability simultaneously. Workforce pressures, pathway redesign, digital integration and health inequalities are all influencing decision-making. Products that can demonstrate how they fit into the realities of NHS delivery are more likely to gain traction than those relying on clinical data alone.
This is why commercialisation can no longer begin at launch.
It starts much earlier.
The decisions made during evidence generation, value proposition development, HTA planning and stakeholder engagement often determine how successfully a product is adopted years later.
Approval is only the beginning
The NHS does not have an innovation problem.
It has an implementation challenge.
Whether discussing urgent and emergency care, prevention, digital transformation or medicines adoption, the same question keeps emerging:
How do we move from knowing what should happen to making it happen?
For life sciences organisations, that means looking beyond approval and thinking more broadly about the path to adoption.
- How will local systems implement this?
- Who needs to be engaged?
- What barriers exist today?
- What does success look like in practice?
These are the questions that ultimately determine whether innovation reaches patients.
A final thought
The most successful healthcare innovations are rarely those with the strongest strategy alone.
They are the ones supported by a clear understanding of NHS reality, strong stakeholder engagement and practical implementation planning.
The NHS will continue to evolve. Structures will change. Priorities will shift. The challenge of turning good ideas into routine care will remain.
How prepared is your organisation for the journey from approval to adoption?
NeoHealthHub helps life sciences companies navigate NHS complexity through insight, strategy and implementation support across HTA, launch, adoption and lifecycle optimisation.